Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Michael J. Keating(The University of Texas MD Anderson Cancer Center), K. B. McCredie(The University of Texas MD Anderson Cancer Center), Jay Schachner(The University of Texas MD Anderson Cancer Center), Craig C. Childs(The University of Texas MD Anderson Cancer Center), Charles Koller(The University of Texas MD Anderson Cancer Center), Emil J. Freireich, S O'Brien(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Moshe Talpaz(University of Michigan–Ann Arbor)
Journal of Clinical Oncology
January 1, 1991
10.1200/jco.1991.9.1.44
Cited by 249

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951